跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HI-6
首页
药物
HI-6
HI-6
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
RECRYSTALLIZED HI-6 DIMETHYLSULFATE
申请人: SOUTHWEST RES INST
优先权: 2019
EP
US
2 件公开
Process for the manufacture of HI-6 dimethanesulfonate
申请人: EDDOLLS JONATHAN
优先权: 2006
US
2 件公开
Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
申请人: WYETH CORP
优先权: 2007
US
3 件公开
Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
申请人: WYETH CORP
优先权: 2006
CN
US
4 件公开
Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
申请人: WYETH CORP
优先权: 2001
US
2 件公开
Antidote liposome for central nervous agent poisoning
申请人: THE GENERAL HOSPITAL OF XINJIANG MILITARY REGION PLA
优先权: 2023
CN
Preparation method of antidote zeolite imidazate skeleton for central nervous agent poisoning
申请人: THE GENERAL HOSPITAL OF XINJIANG MILITARY REGION PLA
优先权: 2025
CN
Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2014
US
药物
反馈